跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 365 条关于
“Suzhou Alphamab”
全部
365
临床试验
54
药物
158
机构
58
资讯
95
去年
Diabetes Pipeline Shows Robust Growth with 200+ Companies Developing Novel Therapies
2年前
Hemophilia A and B Pipeline Advances with Novel Therapies in Clinical Trials
3个月前
Russia Registers First Efanesoctocog Alfa Drug for Haemophilia A as Nanolek Secures EAEU Rights to China's Armocibat
去年
Alphamab Oncology's JSKN033 Shows Promise in HER2-Expressing Solid Tumors
5个月前
WuXi Biologics' Suzhou Biosafety Testing Center Earns Fourth EMA GMP Certification, Enabling 19 Biologics for EU Market
上个月
Pathos AI Licenses Experimental Triple-Negative Breast Cancer Drug from China's Alphamab in $125 Million Deal
去年
Alphamab Oncology Retracts Announcement on JSKN033 Clinical Trial Inclusion
10个月前
Alphamab Oncology's JSKN003 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer
去年
Alphamab Oncology's HER2-Targeting ADC JSKN003 Receives FDA Orphan Drug Designation for Gastric Cancer
2年前
JSKN003 Shows Promise in HER2-Positive Solid Tumors and Platinum-Resistant Ovarian Cancer
第 1 页,共 10 页
上一页
下一页